SBIR Phase I: Combinatorial, controlled, and timed release of parylene encapsulated anti-cancer therapeutics

这个小型企业创新研究(SBIR)第一阶段项目的重点是加强用于癌症局部治疗的药物的组合和定时释放。目前，在乳腺癌手术切除(肿块切除术)后，几乎没有局部消除肿瘤细胞的解决方案。对于能够以持续、安全的方式在本地输送混合药物的微创设备，确实存在着尚未得到满足的需求。我们建议开发一种用于释放紫杉醇和吉西他滨的可植入聚合物缩微胶片装置，这种装置无毒、舒适，在美容上为患者所接受。这项研究的更广泛的影响是：-建立一个多学科计划，整合生物学、材料科学/工程和纳米技术的专业知识，以满足尚未得到满足的医疗需求。-加强乳腺癌的治疗，以及治疗更广泛的其他疾病的下游机会，这些疾病预计将在全球范围内改善患者的结果。-通过新的市场创造经济价值，产品开发和临床应用-生物实验室与洛杉矶和芝加哥地区的教育机构(高中和大学)建立了牢固的关系，并将实习活动作为其创业活动的一部分。一般而言，像生物科技这样的新创业型公司既是经济增长的引擎，也是下一代科学家和工程师的灵感来源。该奖项由《2009年美国复苏和再投资法案》(Public Law 111-5)资助。

This Small Business Innovation Research (SBIR) Phase I project focuses on enhancing combinatorial and timed release of drugs for the localized treatment of cancer. Currently there are few solutions for localized elimination of tumor cells following surgical removal of breast cancer (lumpectomy). There is a real unmet need for minimally invasive devices that locally deliver a cocktail of drugs in a sustained and safe fashion. We propose to develop an implantable polymer-based microfilm device for the release of Paclitaxel and Gemcitabine that is non-toxic, comfortable and cosmetically acceptable to the patient.The broader Impacts of this research are:- Establishment of a multidisciplinary initiative that integrates expertise in biology, materials science/engineering and nanotechnology to address an unmet medical need.- Enhancements in breast cancer treatment, coupled with downstream opportunities to treat a broader array of other diseases that are expected to improve patient outcomes globally.- Economic value through new market creation, product development and clinical applications- Biotic Laboratories has a strong relationship with educational institutions (high schools and universities) in the LA and Chicago area and has engaged intern activity as part of its start-up activities. In general, new entrepreneurial companies such as Biotic serve as both economic growth engines and inspiration to a future generation of scientists and engineers.This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).